Enzyme prodrug therapies (EPTs) have been intensively explored as attractive approaches
to selective activation of systemically administered benign prodrugs by the exogenous …

Cell therapy has reached significant milestones in various life-threatening diseases,
including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor …

Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …

Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative
therapeutic choice in recent years. This novel type of therapy holds tremendous promise for …

Chimeric antigen receptor–engineered (CAR) T-cell therapy is a promising novel
immunotherapy that has the potential to revolutionize cancer treatment. Four CAR T-cell …

Novel targeted therapies are rapidly emerging for the treatment of cancer. With the advent of
new immune targeting agents, understanding the changes in the tumor microenvironment …

The limited efficacy of traditional cancer treatments, including chemotherapy, radiotherapy,
and surgery, emphasize the significance of employing innovative methods. CAR (Chimeric …

CAR T cell research in solid tumors often lacks spatiotemporal information and therefore,
there is a need for a molecular tomography to facilitate high-throughput preclinical …

T lymphocytes are key mediators of the adaptive immune response. Inappropriate or
imbalanced T-cell responses are underlying factors in cancer progression, allergy, and other …

Simple Summary As a novel immunotherapy, chimeric antigen receptor (CAR) T-cell therapy
has achieved encouraging results in leukemia and lymphoma. Furthermore, CAR-T cells …